Sign in
Not yet recruitingNo phase

Traditional Chinese herbal formula compared with mecobalamin for diabetic nerve damage

Tests Zuogui Jiangtang Shuluo Formula against mecobalamin in people with diabetic peripheral neuropathy.

Key facts

Who runs it
The First Affiliated Hospital of Hunan University of Traditional Chinese Medicine
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Registry title
Clinical Study of Zuogui Jiangtang Shuluo Formula in Treating Diabetic Peripheral Neuropathy
Status
Not yet recruiting
People taking part
74 people, planned
Started
15 Aug 2026
Expected to end
15 Sept 2027
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Zuogui Jiangtang Shuluo Formula
  • Mecobalamin
Record updated
18 August 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with type 2 diabetes who have nerve damage in both feet and legs (distal symmetric polyneuropathy). A separate group of healthy volunteers aged 18 to 55 years is also included for comparison.

Age
Patients: 35 to 75 years. Healthy volunteers: 18 to 55 years.
Sex
All sexes can join.
Disease stage
Type 2 diabetes with distal symmetric polyneuropathy (DSPN). Patients must also fit the Chinese medicine pattern of Qi-Yin deficiency with blood stasis. Healthy volunteers need a BMI of 19.0 to 26.0 kg/m² and normal routine tests.
Earlier treatment
No other clinical trial within 2 weeks before treatment starts. No lipid-lowering agents, antibiotics, NSAIDs, antidepressants, immunosuppressants or other traditional Chinese medicines that may affect the blood fat and metabolism tests.
Biomarker or test result
Patients: HbA1c (glycated hemoglobin) between 6.5% (48 mmol/mol) and 9.0% (75 mmol/mol).

Main reasons for not taking part

  • Type 1 diabetes or other special types of diabetes.
  • Pregnant, breastfeeding, planning pregnancy, or taking birth control pills long-term.
  • Nerve damage from other causes, such as multiple sclerosis, Parkinson's disease or spine problems.
  • Stroke, mini-stroke, unstable angina, heart attack or acute diabetes emergency within 3 months.
  • Severe heart, liver or kidney disease, cancer, end-stage diabetic kidney disease, severe eye damage from diabetes, mental illness, or alcohol or drug abuse.

The registry criteria, word for word

Show all 25 criteriaShow less

Other criteria

  • DSPN inclusion criteria:
  • Meet the diagnostic criteria for type 2 diabetes mellitus with distal symmetric polyneuropathy (DSPN) according to Western medicine standards
  • Meet the TCM syndrome differentiation criteria for consumptive thirst complicated with arthromyodynia of the pattern of Qi-Yin deficiency with blood stasis
  • Glycated hemoglobin (HbA1c) between 6.5% and 9.0% (inclusive)
  • Aged 35 to 75 years (inclusive) at the time of screening, regardless of gender
  • Have not participated in any other clinical trial within 2 weeks prior to the start of treatment, and have not taken lipid-lowering agents, antibiotics, non-steroidal anti-inflammatory drugs (NSAIDs), antidepressants, immunosuppressants, or other traditional Chinese medicines that may affect metabolomic and lipidomic profiles
  • Willing to voluntarily participate in the trial and adhere to the 4-week traditional Chinese medicine treatment regimen
  • Right-handed
  • Provide written informed consent and are able to understand and comply with the study protocol requirements, including dietary and exercise recommendations and blood glucose monitoring; DSPN exclusion criteria
  • Patients with type 1 diabetes mellitus or other specific types of diabetes mellitus
  • Women who are pregnant, breastfeeding, planning pregnancy, or taking oral contraceptives long-term
  • Neuropathies caused by other conditions, including but not limited to multiple sclerosis, Parkinson's disease, Guillain-Barré syndrome, epilepsy, spinal cord injury, cervical or lumbar spine lesions (nerve root compression, spinal stenosis, cervical or lumbar degenerative diseases), neuromuscular diseases, severe arterial or venous vascular diseases (venous thrombosis, lymphangitis, etc.), sequelae of cerebrovascular disease, or post-surgical status of lower extremity vasculature
  • History of stroke, transient ischemic attack, unstable angina, or myocardial infarction within 3 months prior to study enrollment
  • History of acute diabetic complications (diabetic ketoacidosis, lactic acidosis, or hyperosmolar hyperglycemic state) within 3 months prior to study enrollment
  • Concomitant severe complications of diabetes, such as end-stage diabetic kidney disease, or proliferative diabetic retinopathy
  • Concomitant severe diseases of the heart, liver, kidney, cerebrovascular system, or malignant tumors, defined as serum creatinine >200 μmol/L, blood urea nitrogen >1.5 times the upper limit of normal, or alanine aminotransferase or aspartate aminotransferase >3 times the upper limit of normal
  • Any infection that, in the investigator's opinion, makes the patient unsuitable for participation prior to study enrollment, including but not limited to urinary tract infection, respiratory infection, or diabetic foot with infection requiring further treatment
  • Patients with psychiatric disorders, cognitive impairment, or inability to cooperate with the study procedures; or individuals with a history of alcohol abuse or drug addiction; Healthy volunteer inclusion criteria:
  • Aged 18 to 55 years (inclusive) at the time of screening, regardless of gender
  • Body mass index (BMI) within the range of 19.0 to 26.0 kg/m² (inclusive). No severe diseases of the heart, liver, kidney, cerebrovascular system, or malignant tumors; routine laboratory tests, electrocardiogram, and chest X-ray are essentially within normal limits
  • Have not participated in any other clinical trial within 2 weeks prior to the start of treatment, and have not taken lipid-lowering agents, antibiotics, non-steroidal anti-inflammatory drugs (NSAIDs), antidepressants, immunosuppressants, or other traditional Chinese medicines that may affect metabolomic and lipidomic profiles
  • Voluntarily sign the informed consent form and are willing and able to cooperate with the investigators to complete the clinical study; Healthy volunteer exclusion criteria:
  • Women who are pregnant, breastfeeding, planning pregnancy, or taking oral contraceptives long-term
  • Patients with psychiatric disorders, cognitive impairment, or inability to cooperate with the study procedures
  • Individuals with a history of alcohol abuse or drug addiction

The main criteria, as questions

These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Are you between 35 and 75 years old?

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Diabetic peripheral neuropathy (DPN) is a common complication of type 2 diabetes mellitus, affecting 35%-50% of diabetic patients. Its pathogenesis involves metabolic disorders induced by hyperglycemia and dyslipidemia, leading to irreversible damage to neurons and vascular endothelial cells. Distal symmetric polyneuropathy (DSPN) is the most representative form, characterized by distal pain, numbness, and sensory loss, which may progress to ulcers, gangrene, and even amputation in severe cases.

Read full original descriptionShow less

Current modern medical treatments for DPN primarily focus on nutritional nerve support, antioxidative stress, and microcirculation improvement, but these approaches are limited in variety and may carry side effects. Traditional Chinese Medicine (TCM) offers advantages including higher safety and diverse therapeutic options.

Based on long-term clinical observation, our research group proposes that the core pathogenesis of DPN is Qi-Yin deficiency with blood stasis obstructing collaterals. The treatment principle is to nourish Yin, supplement Qi, activate blood circulation, and unblock collaterals, with Zuogui Jiangtang Shuluo Formula (ZGJTSLF) as the primary prescription. Previous studies have shown that ZGJTSLF can improve TCSS scores and nerve conduction velocity in DPN patients compared with mecobalamin, but high-level evidence is still lacking.

This randomized, parallel-controlled trial aims to evaluate the clinical efficacy of ZGJTSLF in treating DPN, with TCSS score and nerve conduction velocity as primary outcomes. Metabolomics and lipidomics will be employed to compare metabolic profiles between healthy controls and DPN patients before and after ZGJTSLF treatment, aiming to identify potential biomarkers and explore the underlying mechanisms.

The 2 groups in the trial

  • Zuogui Jiangtang Shuluo Formula GroupTreatment being tested

    Participants in this arm will receive Zuogui Jiangtang Shuluo Formula for 4 consecutive weeks.

    Treatment: Zuogui Jiangtang Shuluo Formula

  • Mecobalamin Control GroupExisting treatment, for comparison

    Participants in this arm will receive mecobalamin tablets for 4 consecutive weeks.

    Treatment: Mecobalamin

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Mechanistic Study of Zuogui Jiangtang Shuluo Formula in Regulating Lipid Metabolism and Inhibiting Ferroptosis for the Prevention and Treatment of Diabetic Peripheral Neuropathy
Plain-language title
Traditional Chinese herbal formula compared with mecobalamin for diabetic nerve damageGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 15 November 2026.
Criteria questions
Built from NCT07771894, who can take part
Record updated
18 August 2026